Sulfasalazine, though previously developed to treat inflammation, has been reported to selectively inhibit xCT, decrease GSH, increase ROS, decrease proliferation and stimulate apoptosis of primary effusion lymphoma (PEL) cells (86). Here, SLC7A11 is linked to primary effusion lymphoma.